Skip to content
MARKETS / NASDAQ / GTBP
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

GT Biopharma, Inc. GTBP

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$-28.4M
Growth
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2020 · Revenue 0.0 · Net income -28.3
-50M-100M201020122014201620182020202220242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
Operating margin Net margin
FY2015 · Operating -33063.0% · Net -79485.2%
-20000%-40000%-60000%201020122014201620182020202220242025
ROE
FY2025 · ROE -1377.4%
-500%-1000%201020122014201620182020202220242025

Each USD of equity lost 1377 cents this year.

Cash & shareholders
USD 229,000.00
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2019 · FCF -3.7
-4M-8M201020122014201620182020202220242025
Net buybacks $ Dividends $
FY2025 · Dividends 229000.0 · Net buybacks —
800001600002025

USD 229,000.00 in dividends went back to shareholders in a year without profit.

Total assetsUSD 8.1M
EquityUSD 5.8M
CashUSD 6.8M
Current ratio3.50×

Equity funds 71% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B·····0.00.0·0.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.1−0.00.0−0.3−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B·····−0.00.0−0.3−0.1−0.0−0.0−0.0····
Income tax $B······0.00.00.00.00.00.00.00.00.0·
Net income $B−0.0−0.0−0.0−0.0−0.1−0.0−0.0−0.3−0.10.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B······−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0·
EPS, diluted $−6.68−6.94−5.64−19.66−2.06−6.45−0.01−5.16−8.60119.91−8.96−0.04−0.01−0.01−0.02−0.03
Dividend / sh $················
Payout %−1···············
ROE %−1377.4−453.4−79.1−124.1···−197.1−123.9·······
Shares out B0.030.000.000.000.030.010.000.050.050.000.000.000.570.500.270.15

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 1 failures · 1 divergences in 71 reconciliationsAUDITED

Reconciled in 14 of 19 fiscal years. 1 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 24 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures1 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image